DJIA 16,204.97 -211.61 -1.29%
NASDAQ 4,363.14 -146.42 -3.25%
S&P 500 1,880.05 -35.40 -1.85%
market minute promo

9.31 -0.20 (-2.10%)

Quote as of

company name or ticker

Recent Quotes

OMED $9.31 -2.10%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $9.52
Previous Close $9.51
Daily Range $9.21 - $9.52
52-Week Range $8.54 - $29.83
Market Cap $280.3M
P/E Ratio -3.76
Dividend (Yield) $0.00 (0.0%)
Volume 186,717
Average Daily Volume 443,230
Current FY EPS -$2.85





News & Commentary Rss Feed

Celgene's Earnings Miss Pales in Comparison to Wall Street's Miss

Rising R&D expenses and slowing Revlimid growth may have caused Celgene to come up short in Q4, but Wall Street appears to have missed something even bigger.

Why OncoMed Pharmaceuticals (OMED) Stock Might be a Great Pick

OncoMed Tanks on Phase II Pancreatic Cancer Study Update

Does Oncomed Pharma Have Any Upside Left?

Why OncoMed Pharmaceuticals' Stock Crashed Today

The biotech's shares sank after independent investigators reported that the company's experimental pancreatic cancer drug appears destined to miss its study goals in an ongoing midstage trial.

Will 2016 Be Celgene Corporation's Best Year Yet?

Celgene outperformed the broader market in 2015, but can the company deliver superior results once more in 2016?

Stocks Hitting 52-Week Lows

OncoMed (OMED) Stock Plummets on Pancreatic Cancer Drug Trial Results

OncoMed Pharma Crashes 40% After Poor Trial Data

Everything You Need to Know About Celgene Summed Up in 5 Slides

Celgene's presentation at the Super Bowl of all healthcare conferences on Monday unearthed plenty of must-know information for investors.

See More OMED News...